Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Cerebroside synthesis as a measure of the rate of remyelination following cuprizone-induced demyelination in brain.
The quality of reports of randomized trials in multiple sclerosis: a review.
Episode 35 with Dr. Daniel Reich on neuroradiology in MS
Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis.
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
The force awakens: insights into the origin and formation of microglia.
Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus.
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.
Episode 8 with Dr. Wendy Macklin on myelination and the zebrafish model of MS
Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies.
The Fourth International Conference on Regulatory T Cells and TH Subsets and Clinical Applications in Human Disease
XI European Meeting on Glia Cells in Health and Disease
GlaxoSmithKline Product Development Pipeline
Delta-9-tetrahydrocannabinol/cannabidiol (sativex(®)): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Multiple sclerosis, vitamin D, and HLA-DRB1*15.
Neuroscience 2014
Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence.
NYSCF Webinar Series: Multiple Sclerosis and the Promise of Stem Cell Research
Teva announces U.S. FDA approval of three-times-a-week COPAXONE® (glatiramer acetate injection) 40mg/mL
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
Mechanism of action of mitoxantrone.
Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.

Pages